Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Biotechnology

Healthcare
$3.89 +0.79%

+$0.03 today

Market cap
$169.16M
Beta
1.24
P/E (TTM)
1.4
EPS (TTM)
$2.70
Dividend yield
6.54%
52W Low $1.98High $5.01

Volume 0.16M

Average 0.16M

ORMP Purchases of Investments

Cash used to buy marketable securities and other investments.

Oramed Pharmaceuticals Inc.NASDAQ: ORMP

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments grows, but more slowly than its trailing trend

Q1 FY2026 purchases of investments of $13.86M (cash outflow) rose 64.1% year over year, behind the +73.6% change in trailing-twelve-month purchases of investments. Sequentially, it fell 38.9% from the prior quarter. Over 3 fiscal years it compounded at -16.9% a year.

Context

  • Purchases of investments amounted to 4425.3% of revenue in FY2025.
  • Purchases of investments grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +64.1% toward the trailing-twelve-month pace of +73.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$13.86M-38.9% QoQ
Last fiscal yearDec 2025
-$88.51M+58.7% YoY
LTMMar 2026
-$104.51M+73.6% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+64.1%——
1 year+58.7%——
3-year CAGR-16.9%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(88.51M) USD
Year-over-year change
-58.7%

Purchases of Investments vs competitors

How ORMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +73.6% is the 4th highest of 8, against a peer median of +46.1%.
  • Over three fiscal years its annual growth of -16.9% compares with a peer median of -25.0%.
ORMP Competitors
Purchases of Investments for ORMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$202.4M USD+485.0%+20.0%128.9%
KLRSKalaris Therapeutics IncLTM Mar 2026$104.87M USD———
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$104.51M USD+73.6%-16.9%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$91.01M USD+33.1%-19.0%1277.8%
IFRXInflaRx N.V.LTM Mar 2026€46.43M EUR+46.1%-11.8%158301.3%
STTKShattuck Labs, Inc.LTM Mar 2026$43.48M USD-21.3%-31.0%4348.3%
CNTBConnect Biopharma Holdings LimitedFY2025$30.47M USD+97.2%-35.5%47609.4%
IMAImageneBio IncLTM Mar 2026$4.15M USD-90.4%-63.6%—
COYACoya Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
CLNNClene Inc.LTM Mar 2026$0 USD+100.0%—0.0%
CNTXContext Therapeutics Inc.LTM Mar 2026$0 USD———
Peer median (excluding ORMP) —+46.1%-25.0%1277.8%

Competitors are the stored peer set for ORMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Aug 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(22.24M)(36.56M)5.53M(19.06M)64.02M
Depreciation & Amortization77K58K196K193K121K
Deferred Income Tax00007.91M
Stock-Based Compensation00005.99M
Change in Working Capital(1.32M)(943K)(2.7M)3.2M(1.91M)
Accounts Receivables00000
Inventory00000
Accounts Payables2.06M(376K)(2.23M)3.53M1.13M
Other Working Capital(3.38M)(567K)(471K)(325K)(3.04M)
Other Non-Cash Items2.3M8.75M(13.32M)7.26M(85.28M)
Operating Cash Flow(21.18M)(28.7M)(10.3M)(8.41M)(9.15M)
Capital Expenditures(375K)(496K)(254K)(18K)(1.93M)
Acquisitions (Net)1.5M24K00(7.25M)
Purchases of Investments(53.82M)(154.41M)(190.92M)(55.76M)(88.51M)
Sales of Investments30.43M185.09M118.14M161.65M96.88M
Other Investing Activities(1K)2K0(60K)6.25M
Investing Cash Flow(22.26M)30.21M(73.04M)105.82M5.44M
Debt Repayment——49.55M(49.55M)0
Common Stock Issued101.39M11.56M2.43M00
Common Stock Repurchased000(2.48M)(4.74M)
Dividends Paid00000
Other Financing Activities000(2K)0
Financing Cash Flow101.39M11.56M51.98M(52.04M)(4.74M)
Effect of Forex Changes2K(49.85M)(54K)(4K)(30K)
Net Change in Cash57.95M(36.78M)(31.41M)45.37M(8.47M)
Free Cash Flow(21.56M)(29.2M)(10.55M)(8.43M)(11.08M)

Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Intrinsic Alpha fair value

Locked

Current Price

$3.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.